<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801591</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci GH AQ CT-POR</org_study_id>
    <nct_id>NCT02801591</nct_id>
  </id_info>
  <brief_title>Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET</brief_title>
  <official_title>Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of Poor Ovarian Response (POR) Clinical Outcome in Patients Undergoing in Vitro Fertilization / Embryo Transfer (IVF/ET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection
      assisted in the treatment of the patients with poor ovarian response in vitro fertilization
      and embryo transfer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of retrieved oocytes</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of high quality embryos</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos transferred</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Poor Ovarian Response</condition>
  <arm_group>
    <arm_group_label>GH AQ</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional ovarian stimulation proctol without rhGH</intervention_name>
    <arm_group_label>GH AQ</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Poor ovarian response
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age 30-42 years old.

          -  Diagnosis of POR (2011 ESHRE Bologna Standard).

          -  At least two previous IVF failure history.

          -  Voluntarily to sign the &quot;informed consent&quot;.

        Exclusion Criteria:

          -  Severe acute and chronic liver and kidney disease，Such as liver cirrhosis, acute and
             chronic renal failure, hepatitis B virus activity period, etc.；Liver and kidney
             dysfunction.

          -  Endocrine and metabolic diseases，eg, diabetes、Thyroid function hyperthyroidism,
             Thyroid dysfunction, cushing's syndrome, hyperprolactinemia，hyperandrogenism.

          -  Related diseases affecting outcome of IVF pregnancy，eg, hydrosalpinx,
             hysteromyoma≥4cm, adenomyosis, stage III and IV endometriosis, untreated endometrial
             lesions, uterine malformation, genital tuberculosis, malignant tumor of reproductive
             system （include endometrial carcinoma, cervical carcinoma, ovarian cancer, fallopian
             tube carcinoma）.

          -  Allergic to E. coli expression product and its excipients.

          -  Subjects who participated in the past three months or are participating in other drug
             clinical researchers.

          -  IVF failure history≥3.

          -  The researchers consider who is not suitable for enrolling the group.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Na Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Yang</last_name>
    <phone>010-82265080</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Yang</last_name>
      <phone>010-82265080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Peking University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>June 12, 2016</last_update_submitted>
  <last_update_submitted_qc>June 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

